|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
| Address1 | 2000 GALLOPING HILL ROAD |
Address2 |
|
| City | KENILWORTH |
State | NJ |
Zip Code | 07003 |
Country | USA |
3. Principal place of business (if different than line 2)
| City |
|
State |
|
Zip Code |
|
Country |
|
|
5. Senate ID# 24908-12
|
||||||||
|
6. House ID# 313040000
|
||||||||
| TYPE OF REPORT | 8. Year | 2022 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
| 10. Check if this is a Termination Report | Termination Date |
|
11. No Lobbying Issue Activity |
| INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| 12. Lobbying | 13. Organizations | ||||||||
| INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
| Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
|
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
|||||||||
| Signature | Digitally Signed By: Bob Filippone |
Date | 1/20/2023 8:50:28 AM |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act
H.R. 19 Lower Costs, More Cures Act of 2021
H.R. 1550, PREVENT HPV Cancers Act of 2021
H.R. 2873, Affordable Prescriptions for Patients Through Promoting Competition Act of 2021
H.R. 3173, Improving Seniors Timely Access to Care Act of 2021
H.R. 3655, Vaccine Injury Compensation Modernization Act of 2021
H.R. 3932/S. 2079, Pioneering Antimicrobial Subscriptions To End Up surging Resistance (PASTEUR) Act of 2021
H.R. 4127, Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act of 2021
H.R. 5416, Give Kids a Chance Act
H.R. 5801, Help Ensure Lower Patient (HELP) Copays Act
H.R. 6584, Diverse and Equitable Participation in Clinical Trials (DEPICT) Act
H.R. 6963, Accelerated Approval Integrity Act of 2022
H.R. 7559, Prescription Information Modernization Act of 2022
H.R. 7667, Food and Drug Amendments of 2022
S. 1435, Affordable Prescriptions for Patients Act of 2021
S. 1712, Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act of 2019
S. 2774, Pride in Patent Ownership Act
S. 2891, Restoring the America Invents Act
S. 2543 (116th Congress) Prescription Drug Pricing Reduction Act of 2019
S. 1895 (116th Congress) Lower Health Care Costs Act
S. 4348, Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act of 2022
S. 4760, (116th Congress) The PASTEUR Act
Issues relating to,
340B program integrity;
340B of the Public Health Services Act;
340B policy;
340B issues;
340B drug pricing program;
Drug pricing;
Drug Pricing reforms - international reference prices and government price setting;
Anti-microbial Resistance;
Vaccines;
COVID-19 vaccines;
COVID-19 therapeutics coverage issues;
COVID-19 Pandemic response;
Cost and value of medicines;
Respiratory Syncytial Virus (RSV) immunization;
Vaccines catch up;
Vaccine provisions;
Vaccine Issues, including return to care access, and pandemic-related policy;
Package inserts, labeling issues, and E-Labeling authorization legislation;
Pharmaceutical Supply Channel issues;
Prescription Drug User Fees Act (P.L. 102-571);
Inflation Reduction Act (P.L. 117-169), issues relating to drug pricing provisions;
Animal Drug User Fee Act (P.L. 108-130);
Prescription drug cost-sharing;
Accelerated approval reform;
Food and Drug Administration Safety and Landmark Advancements (FDASLA);
Executive Order 13937, Access to Affordable Life-Saving Medications;
FY-2023 Budget and Appropriations Legislation;
Intellectual property protection;
WTO Trade-Related Aspects of Intellectual Property Rights (TRIPS) Agreement;
Animal Health;
Animal Health Technology Issues;
One Health Issues;
Rural Broadband Issues;
General pharmaceutical issues;
Farm Bill 2023;
Animal Drug User Fee Act 2023
Vaccine Injury Compensation Program.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, White House Office, Commerce - Dept of (DOC)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Bradley |
Rossin |
|
|
|
Liz |
Schwartz |
|
|
|
Erin |
Darling |
|
|
|
Adam |
Huftalen |
|
|
|
Bob |
Filippone |
|
|
|
Bradford |
Tallamy |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act, provisions related to Medicare Part B
H.R. 2716, Consolidated Appropriations Act, 2023, provisions relating to Medicare Part D emergency use authorization coverage
H.R. 5376, Build Back Better Act
S. 476 (116th Congress) Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2019
S. 2543 (116th Congress) Prescription Drug Pricing Reduction Act of 2019
Issues relating to,
Medicaid;
Medicare;
Medicare Part B and D drug pricing issues;
Medicare Part D, Six Protected Classes;
Prior authorization process under Medicare Advantage plans;
340B program integrity;
340B of the Public Health Services Act;
340B drug pricing program;
Drug Pricing;
Prior Authorization under Medicare Advantage Plans;
FY-2023 Budget and Appropriations Legislation.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Bradley |
Rossin |
|
|
|
Liz |
Schwartz |
|
|
|
Erin |
Darling |
|
|
|
Adam |
Huftalen |
|
|
|
Bob |
Filippone |
|
|
|
Bradford |
Tallamy |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TAX
16. Specific lobbying issues
H.R. 5376, Inflation Reduction Act of 2022, including provisions relating to budget reconciliation tax provisions
Issues related to,
Tax reform and tax policy, generally;
Tax Cuts and Jobs Act of 2017 (P.L. 115-97);
Tax provisions of Budget Reconciliation.
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Bradley |
Rossin |
|
|
|
Adam |
Huftalen |
|
|
|
Liz |
Schwartz |
|
|
|
Bradford |
Tallamy |
|
|
|
Bob |
Filippone |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
| Address |
|
||||||
| City |
|
State |
|
Zip Code |
|
Country |
|
21. Client new principal place of business (if different than line 20)
| City |
|
State |
|
Zip Code |
|
Country |
|
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
| 1 |
|
3 |
|
||||||
| 2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
| Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
||||||||||||||
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
| 1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
| Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% | |||||||||||||
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
| 1 | 3 | 5 |
| 2 | 4 | 6 |
CONVICTIONS DISCLOSURE
29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery,
extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?
| Lobbyist Name | Description of Offense(s) |